Regenxbio (RGNX) Reports Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II
Tweet Send to a Friend
REGENXBIO Inc. (NASDAQ: RGNX) today announced financial results for the quarter ended September 30, 2018 and recent operational highlights ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
